Multicenter Retrospective Study to Evaluate the Safety and Efficacy of Chemoradiotherapy with Carboplatin for Limited Stage-Small Cell Lung Cancer unfit for CDDP

Multicenter Retrospective Study to Evaluate the Safety and Efficacy of Chemoradiotherapy with Carboplatin for Limited Stage-Small Cell Lung Cancer unfit for CDDP - CHAOS trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057834

Enrollment

500

Registered

2025-05-12

Start date

2025-02-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Limited Stage-Small Cell Lung Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)The diagnosis of small cell lung cancer has been pathologically confirmed by cytology or histology. 2)The disease is confirmed to be limited stage (LD), including cases of post-surgical recurrence. 3)The ECOG performance status at the start of treatment is between 0 and 2. 4)Chemoradiotherapy including carboplatin (CBDCA) has been administered. 5)The patient's age at the start of treatment is 18 years or older.

Exclusion criteria

Exclusion criteria: 1)Individuals deemed inappropriate for inclusion in the study by the principal investigator. 2)Individuals who declined to participate in this study through the opt-out process.

Design outcomes

Primary

Measure	Time frame
Two-year survival rate	—

Countries

Japan

Contacts

Public ContactYuta Yamanaka

Kansai Medical University Hospital Department of Thoracic Oncology

yuta1106yamanayt@gmail.com09087941603

Outcome results